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Abstract Colorectal cancer stem cells (CSCs) drive
tumor growth and are suggested to initiate distant metas-
tases. Moreover, colon CSCs are reportedly more resistant
to conventional chemotherapy, which is in part due to
upregulation of anti-apoptotic Bcl-2 family members. To
determine whether we could circumvent this apoptotic
blockade, we made use of an inducible active caspase-9
(iCasp9) construct to target CSCs. Dimerization of iCasp9
with AP20187 in HCT116 colorectal cancer cells resulted
in massive and rapid induction of apoptosis. In contrast to
ﬂuorouracil (5-FU)-induced apoptosis, iCasp9-induced
apoptosis was independent of the mitochondrial pathway as
evidenced by Bax/Bak double deﬁcient HCT116 cells.
Dimerizer treatment of colon CSCs transduced with iCasp9
(CSC-iCasp9) also rapidly induced high levels of apopto-
sis, while these cells were unresponsive to 5-FU in vitro.
More importantly, injection of the dimerizer into mice that
developed a colon CSC-iCasp9-induced tumor resulted in a
strong decrease in tumor size, an increase in tumor cell
apoptosis and a clear loss of CD133
? CSCs. Taken toge-
ther, our data indicate that dimerization of iCasp9 cir-
cumvents the apoptosis block in CSCs, which results in
effective tumor regression in vivo.
Keywords Cancer stem cell  Inducible caspase-9 
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Introduction
Cancer stem cells (CSCs), also called tumor-initiating
cells, were ﬁrst identiﬁed in haematological malignancies,
but more recently these cells were also described in solid
tumors, like colorectal cancer (CRC) [1–4]. CSCs are a
subpopulation of cells within the tumor that contain self-
renewal capacity and the ability to differentiate. Therefore,
they are thought to be the driving force behind tumor
growth and metastasis. In vitro experiments have shown
that colon CSCs are more resistant to treatment with ﬂu-
orouracil (5-FU) and oxaliplatin compared to their more
differentiated progeny [3, 5] and therefore, CSCs are
thought to be responsible for tumor recurrence after
treatment.
Chemoresistance of tumor cells can be caused by
alterations in the expression of apoptotic and anti-apoptotic
genes [3]. Apoptosis can be triggered by the extrinsic
pathway, initiated by ligation of death receptors on the cell
surface leading to caspase-8 activation, or by the intrinsic
pathway, which leads to cytochrome c release from the
mitochondria [6]. Release of cytochrome c is regulated by
Bax and Bak-dependent mitochondrial permeabilization
and is counteracted by the anti-apoptotic Bcl-2 family
members. Cytochrome c release is a crucial step in the
assembly of the apoptosome, which in effect results in
caspase-9 activation through induced proximity and
subsequently cumulates in proteolytic cleavage and
thereby activation of the downstream executioner caspases-
3 and -7.
Evasionofapoptosisisoneofthehallmarksofcancer[7].
Resistance to chemotherapy-induced apoptosis in CRC
tumors is in part due to upregulation of anti-apoptotic mol-
ecules and downregulation of pro-apoptotic molecules. For
instance, the expression level of anti-apoptotic molecule
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DOI 10.1007/s10495-011-0692-zBcl-2 has been reported to increase during the early
stages of colorectal tumorigenesis [8]. On the other hand,
pro-apoptotic molecules like Bax and Bak [9] are
decreased in CRC tumors. Low levels of pro-apoptotic
molecule Bax have been shown to correlate to 5-FU
resistance [10]. In addition, more than 50% of colon
tumors with defects in mismatch repair harbor mutations
in Bax, thereby compromising its function in apoptosis
[11]. CRCs therefore appear to escape from therapy-
induced apoptosis by changes in the expression of apop-
tosis-regulatory genes.
Unlike executioner caspases, such as caspase-3, that are
activated by cleavage, caspase-9 undergoes a conforma-
tional change when two caspase-9 molecules are brought
into close proximity. This opens up the catalytic site and
unleashes the proteolytic activity. Based on the same
principle an inducible system has been developed where
the catalytic domain of caspase-9 is fused to a modiﬁed
FK506-binding domain (FKBP) that can be homodimer-
ized by addition of an optimized chemical inducer of
dimerization (CID) AP20187 [12]. The dimerizer is
membrane-permeable and binds at subnanomolar concen-
trations to the modiﬁed FKBP, while the afﬁnity for the
endogenous FKBP is 1,000-fold lower. Therefore addition
of the dimerizer brings two inducible caspase-9 (iCasp9)
molecules into close proximity and thereby rapidly acti-
vates downstream executioner caspases in a cytochrome
c-independent fashion. In contrast to other inducible sui-
cide systems, such as the HSV-1-derived thymidine kinase
(HSV-TK)/ganciclovir (GCV) method, the mode of action
of iCasp9 does not rely on proliferation, which makes it
ideal to target CSCs, as these have been shown under
certain conditions to be quiescent or slow cycling [13–16].
In addition, HSV-TK has been shown to induce a bystander
effect, since the prodrug GCV, when converted to its active
form by HSV-TK, can spread to other cells and also exert
its inhibitory function in cells that do not express HSV-TK.
In contrast, iCasp9-induced apoptosis is cell autonomous
and a more reliable method to selectively target individual
cells without collateral damage. Lastly, since caspase-9 is
downstream of the mitochondria the sensitivity of cells to
its activation should be independent of the Bcl-2 family of
proteins.
The iCasp9 construct has been tested in an in vitro and
in vivo xenograft model for prostate cancer [17], but the
cytotoxic effect on CSCs was not taken into consideration
in this study. Since CSCs are known to be resistant to
conventional therapy, we decided to study the effect of
dimerization of iCasp9 in these cells. We show here that
CRC cells that have lost pro-apoptotic proteins are still
responsive to the dimerization of iCasp9. More impor-
tantly, colon CSCs are very effectively killed by dimer-
ization of iCasp9 both in vitro and in vivo.
Materials and methods
Cell lines, culture, vectors, transduction, selection
and dimerizer treatment
HCT116 lines were derived from Dr. G. C. Chinnadurai
(St. Louis University School of Medicine, USA) and cul-
tured in Dulbecco’s Modiﬁed Eagle Medium (DMEM,
Invitrogen) containing 8% fetal calf serum (FCS), 2 mM
glutamine, 100 U/ml penicillin and 100 lg/ml streptomy-
cin. The CSC line, obtained from a primary carcinoma
under standard medical ethical procedures of the Academic
Medical Center was derived and cultured as described
previously [3]. PMX-iCasp9-IRES-GFP and pMX-IRES-
YFP virus were produced in Phoenix cells and virus was
harvested after 48 h. Transduction was performed over-
night with addition of 10 lg/ml polybrene. Transduced
cells were selected by sorting for GFP/YFP expression.
Treatment was performed with 10 nM dimerizer AP20187
obtained from ARIAD Pharmaceuticals (Cambridge, MA,
USA) or 500 lg/ml 5-FU.
FACS analysis, active caspase-3 assay, Annexin-V
staining and limiting dilution assay (LDA)
Cell death was analyzed by FACS using PI-positivity
(200 ng/ml) and apoptosis was analyzed by DNA frag-
mentation using a Nicoletti assay. To this end cells were
incubated overnight in Nicoletti buffer (0.1% Na-citrate,
0.1% Triton-X-100 and 50 lg/ml PI in H20) and analyzed
the next day. Activity of caspase-3 was analyzed by
CaspGLOW Red Active Caspase-3 Staining Kit (K193-
100, Biovision) according to manufacturer’s protocol. Cells
were stained for CD133 (AC133, Miltenyi) to identify the
CSC fraction. Early apoptosis was analyzed by Annexin-V
staining (550474, BD Biosciences). Xenografts were dis-
sociated with 1.5 mg/ml of collagenase II (C6885, Sigma)
and 20 lg/ml of hyaluronidase (H4272, Sigma) at 37C for
30 min. Cells were then stained in PBA (PBS with 1%
BSA and 0.02% sodium azide) for PE-anti-Epcam (EBA-1,
BD Biosciences) and APC-anti-CD133 (AC133, Miltenyi).
All analyses were performed on the FACS Canto (BD
Biosciences), while further analyses were performed in
FlowJo (BD Biosciences). For LDA, cells were deposited
by FACSAria in a 96-well plate as 1, 2, 4, 8, 10, 12, 16, 20
and 24 cells per well in at least 8 wells per condition. After
two weeks, the presence of spheroids in each well was
scored.
Cell lyses, western blotting and antibodies
Cells were lysed in Triton-X-100 lysis buffer (20 mM Tris
HCl, pH 7.4, 137 mM NaCl, 10% Glycerin, 1% Triton-X-100,
Apoptosis (2012) 17:528–537 529
1232 mM EDTA, 2 lg/ml Aprotinin, 10 lg/ml Leupeptin).
Protein amounts were measured by BCA protein assay
(Thermo Scientiﬁc Pierce) according to the manufacturer’s
protocol. Per lane, 20 lg protein was loaded on 12% acryl
amide gels and blotted onto nitrocellulose membrane.
Unspeciﬁc binding was blocked in blocking buffer
(LICOR). Membranes were incubated overnight at 4C
with rabbit-anti-cleaved caspase 3 (9661, Cell Signaling),
rabbit-anti-PARP (9542, Cell Signaling) or mouse-anti-
beta I tubulin (T7816, Sigma). After washing in PBS-0.2%
Tween, membranes were incubated for 1 h at RT with
IRDye 680-anti-rabbit IgG (LICOR) or IRDye 800 anti-
mouse IgG (LICOR). Membranes were developed with the
Odyssey (LICOR).
In vivo tumor growth
All animal experimentation was approved by the Dier
Experimentele Commissie (DEC) of the institute. C002-
iCasp9-IRES-GFP cells were injected subcutaneously in
male athymic Balb/cOlaHsd-Foxn1
nu mice (Harlan). In the
ﬁrst experiment, when tumors reached an average size
of 200 mm
3, the mice were treated with either one (day 0)
or two intraperitonial injections (day 0, 2) of 1 mg/kg
AP20187 dissolved 4% ethanol, 10% PEG-400 and 86%
PBS-2%Tween. In the second experiment, treatment was
either started at the same day of the injection of the tumor
cells or after the tumors reached an average size of
200 mm
3. Mice were treated every day with 0.5 mg/kg
(intervention) or 1 mg/kg (therapeutic) AP20187 for 5
consecutive days. Tumor size was measured twice a week
by caliper.
Immunohistochemistry and antibodies
Tumors were ﬁxed in paraformaldehyde overnight and
embedded in parafﬁn. Slides were cut, deparafﬁnized and
rehydrated. Endogenous peroxidase was blocked in meth-
anol with 0.3% H202 for 20 min. Antigen retrieval was
performed by boiling the slides in antigen unmasking
buffer (H-3300, Vector Brunschwig) for 10 min. Biotin-
blocking was performed with the avidin/biotin blocking kit
(00-4303, Zymed). Slides were blocked with 10% FCS in
PBS, and then incubated overnight at 4C with rabbit-anti-
Ki67 (SP6, Neomarkers), rabbit-anti-FKBP12 (PA1-026A,
Afﬁnity Bioreagent) or mouse-anti-cytodeath (M30,
Peviva). After washing, the slides were incubated for 1 h at
RT with biotin-anti-mouse IgG (62-6540, Zymed) or bio-
tin-anti-rabbit (E0432, Dako). After washing, the slides
were incubated with AB Complex/HRP (K0355, Dako) and
subsequently stained with DAB (K3468, Dako). Counter-
stain was performed with hematoxyline. Sides were dehy-
drated and mounted with perpex.
Results
Apoptosis induction by dimerization of iCasp9
is independent of Bax/Bak and XIAP
Tumor cells that are resistant to conventional chemother-
apy, often downregulate pro-apoptotic molecules and/or
upregulate anti-apoptotic molecules to achieve this resis-
tance. To mimic this, we made use of the CRC cell line
HCT116 deﬁcient for both Bax and Bak [18, 19], referred
to as DKO cells. Bax and Bak are required for cytochrome
c release from the mitochondria and thus subsequent cas-
pase activation [20–22]. Loss of only one of the pro-
apoptotic Bcl-2 family members does not prevent apoptosis
in most cases as Bax and Bak are redundant [23, 24].
However, absence of both Bax and Bak makes cells highly
resistant to mitochondrial-dependent caspase activation
after exposure to various stress stimuli and chemothera-
peutic insults [22, 25]. One such stimulus is 5-FU, a
pyrimidine analogue that upon cell entry is converted into
different cytotoxic metabolites and incorporated into the
DNA and RNA, thereby inducing cell cycle arrest and
apoptosis. In agreement, treatment of WT HCT116-GFP
cells with 500 lg/ml 5-FU for 24 h induced cell death as
measured by PI
? cells. This coincides with the induction of
apoptosis using either DNA fragmentation or cleavage of
PARP and caspase-3 as read-out (Fig. 1a–c). In contrast,
5-FU treatment of the DKO HCT116-GFP cells did not
induce any signs of cell death or apoptosis (Fig. 1a–c),
conﬁrming that loss of Bax and Bak causes resistance to
apoptosis induced by 5-FU.
Next, we set out to test whether the iCasp9 construct
would induce apoptosis in the mitochondrial pathway-
deﬁcient DKO cells. To this end, we transduced WT
HCT116 and the DKO cells with a vector encoding iCasp9-
IRES-GFP. Treatment with 10 nM of AP20187 dimerizer
resulted in a time-dependent reduction of GFP
? cells and a
concomitant increase in PI
? cells after 24 h, showing that
cell death is induced by dimerization (Fig. 1d, e). Only the
iCasp9-IRES-GFP expressing cells die upon addition of
dimerizer, while control transduced (PMX-YFP) showed
no response to treatment, indicating that the cytotoxic
effect is dependent on the presence of iCasp9. To directly
show that the cell death is a result of apoptosis, we
determined the effect of dimerizer on caspase-3 activation
and DNA fragmentation. This revealed that the addition of
dimerizer results in an extremely rapid onset of apoptosis.
Both caspase-3 activation and DNA fragmentation were
detected already after 1 h of dimerizer treatment, and
PARP was even fully processed at this time point (Fig. 1f, g).
Importantly, at the later time points tumor cells were
completely disintegrated and we even failed to isolate
sufﬁcient amounts of protein from these dead cells as
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Fig. 1 Apoptosis induction by dimerization of iCasp9 is independent
of Bax/Bak and XIAP. a–c HCT116 control cells and HCT116 cells
deﬁcient for Bax and knockdown for Bak (DKO) were treated with
500 lg/ml 5-FU for 24 h, after which they were analyzed by FACS
for PI-exclusion (a), apoptotic nuclei (b), and by western for cleaved
caspase 3 and cleaved PARP (c). Tubulin was used as a loading
control. d–f WT HCT116 and DKO HCT116 cells were transduced
with either pMX-iCasp9-IRES-GFP or control vector pMX-IRES-YFP
after which they were treated with 10 nM of dimerizer AP20187 for
different time points, cells were analyzed by FACS for GFP-positivity
(d), PI-exclusion (e) and apoptotic nuclei (f). WT HCT116 and DKO
HCT116 cells iCasp9-IRES-GFP or pMX-IRES-YFP were analysed
for g 5-FU and h dimerizer-induced caspase-3 activity after 16 and
1 h, respectively or i by western for cleaved caspase 3 and cleaved
PARP after dimerizer treatment at different time points. Tubulin was
used as a loading control
Apoptosis (2012) 17:528–537 531
123evidenced by the lack of tubulin in the samples. As
expected, the induction of apoptosis is dependent on the
presence of iCasp9 and not observed in HCT116 cells
transduced with a control vector.
Interestingly, when DKO HCT116 cells, transduced
with iCasp9, were treated with dimerizer, they responded
in a similar way as the WT HCT116 cells. Also, these DKO
cells displayed a quick apoptotic response to the dimerizer,
while they resist 5-FU. The dimerizer induced quick DNA
fragmentation, PARP and caspase-3 cleavage (Fig. 1f, g, i).
In addition, the increase in PI
? cells (Fig. 1e) and decrease
in GFP
? cells (Fig. 1d) was found after 24 h, indicating
that dimerization of iCasp9 can induce a robust and efﬁ-
cient cell death, even when Bax and Bak are not present.
Taken together, the current data indicate that dimerizer-
induced cell death is dependent on the presence of the
iCasp9 construct, but the effectiveness does not depend on
upstream signalling molecules in the apoptosis pathway
like Bax and Bak.
Dimerization of iCasp9 in CSCs induces apoptosis
in vitro
Since CSCs are thought to be the cells within a tumor that
are resistant to conventional therapy, we switched to a
more relevant in vitro system, namely that of primary
spheroid culture, to test our iCasp9 construct. A CSC
spheroid culture, derived from a primary CRC [4], was
transduced with the pMX-iCasp9-IRES-GFP construct and
subsequently single-cell cloned to avoid cell-to-cell varia-
tion in integration site or number of the retroviral vector.
Two clones were used for further studies and initially
treated with 10 nM of dimerizer AP20187 for different
periods of time. Also in these CSC cultures, loss of GFP
?
cells and induction of PI
? cells was clearly observed
starting 24 h after treatment, indicating that cell death was
induced. Similarly to the situation in HCT116 cells, rapid
and robust induction of apoptosis as measured by DNA
fragmentation, PARP and caspase-3 cleavage was found
already after 1 h of treatment (Fig. 2a–d).
As these spheroid cultures do not only contain CSCs, but
also more differentiated cells, as shown previously by our
group [26], we decided to compare the effect of dimer-
ization of iCasp9 to treatment with 5-FU in a more speciﬁc
test that allows to discriminate CSCs from their differen-
tiated progeny. This assay allows us to speciﬁcally analyse
apoptosis induction within the CSC population and com-
pare it directly to the more differentiated tumor progeny.
To this end, we stained spheroid cultures for the CSC
marker CD133 [1–3] and analyzed the activity of caspase-3
in CD133
high (i.e. CSCs) versus CD133
low cells (i.e. more
differentiated tumor cells). In addition, as a supplement
measurement for apoptosis we studied the expression of the
early apoptosis marker Annexin-V. Treatment of CSCs for
48 h with 500 lg/ml 5-FU induced apoptosis in the more
differentiated cells, whereas the CD133
high CSCs were
resistant (Fig. 2e, f). In contrast, treatment for 1 h with
dimerizer induced apoptosis in both the CD133
high and the
CD133
low population (Fig. 2e, f), indicating that CSCs
which are normally resistant to conventional therapy can be
targeted by dimerization of iCasp9.
To functionally prove that CSCs are killed by dimer-
ization of iCasp9, we analysed the clonogenic capacity of
CSCs after dimerization treatment by performing a limiting
dilution assay (LDA). This assay determines the clono-
genic growth of single cells derived from the spheroid
cultures and is a measure for the viability of the CSCs.
Spheroid cells were either pre-treated for 1 h with dimer-
izer or left untreated and subsequently deposited by FACS
in a limiting dilution fashion. After 2 weeks, outgrowth of
spheroids was scored. Untreated CSCs had a clonogenic
capacity of approximately 1 in every 7 cells. However, pre-
treatment of CSC with dimerizer, resulted in a dramatic
decrease in clonogenicity to only 1 in every 400 cells
(clone #1) or even a complete absence of spheroids after
two weeks (clone #2) (Fig. 2g, h). Of note, the spheroids
that did grow out after dimerization treatment were all
GFP
-, suggesting that they had lost the construct and
thereby were rendered resistant to the induction of apop-
tosis. Altogether, these data show that CSCs, marked by
CD133, display resistance to 5-FU treatment in vitro, while
dimerization of iCasp9 also induces apoptosis in the CSC
fraction and thereby loss of clonogenicity.
Dimerization of iCasp9 induces apoptosis and growth
delay in vivo
To test the in vivo efﬁcacy of the iCasp9-induced CSC
apoptosis, the CSC-iCasp9-IRES-GFP cells were injected
subcutaneously in immunodeﬁcient mice and allowed to
grow. When tumors had reached a size of *200 mm
3,
mice were treated either once or twice with 1 mg/kg
AP20187 intraperitoneally or left untreated. Treatment led
in both cases to a reduction in tumor size for around
15 days, especially when compared to the untreated con-
trol. However, after this initial reduction, tumors started to
grow out again. To determine whether regrowth was due to
an escape from therapy due to the availability of the
dimerizer or a simple silencing of the iCasp9 construct, we
retreated the mice for a second time with dimerizer and
observed a reduction in tumor size. This indicates that the
iCasp9 is still present in a fraction of the tumor cells, yet
we also observed a more rapid regrowth (Fig. 3a).
H&E staining of the treated tumors revealed that
dimerization of iCasp9 induced a massive loss of cells in
the tumor, which was caused by cell death, as shown by the
532 Apoptosis (2012) 17:528–537
123apoptotic cytodeath (M30) staining. Staining for prolifer-
ation marker Ki67 shows that cells that do survive the
treatment are still highly proliferating, explaining the rapid
re-growth of the tumors (Fig. 3b). When tumor cells were
analyzed by FACS 48 h after the last treatment, a two- to
fourfold relative decrease in epithelial cells was found,
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Fig. 2 Dimerization of iCasp9 induces apoptosis in CSCs in vitro.
a–d Spheroid culture derived from a primary colon carcinoma was
transduced with pMX-iCasp9-IRES-GFP and single-cell cloned by
FACS. Two clones were treated with 10 nM dimerizer AP20187 for
different time points. Cells were analyzed by FACS for GFP-
positivity (a), PI-exclusion (b), apoptotic nuclei (c) and by western
for cleaved caspase 3 and cleaved PARP (d). Tubulin was used as a
loading control. e, f CSCs with iCasp9 cells were treated for 48 h with
500 lg/ml 5-FU or for 1 h with 10 nM dimerizer. Next, early markers
of apoptosis, Annexin-V staining (e) and activity of caspase-3 were
measured (f). g, h The clonogenic capacity of the C002-iCasp9 after
dimerizer treatment was analyzed by LDA, showing that CSCs are not
resistant to apoptosis induction by dimerization of iCasp9. The graphs
represent either the outgrowth of spheroids (g) or the clonogenic
fraction calculated by ELDA (h)
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123indicating that the tumor cells with iCasp9 were indeed
targeted. In addition, a signiﬁcant loss of GFP-positivity
was observed. This conﬁrms our observations with the
second treatment of dimerizer and suggests that the iCasp9
construct in the remaining epithelial cells is either lost or
inactivated. In addition, loss of expression of CSC marker
CD133 was found, indicating that the CSCs were indeed
targeted (Fig. 3c, d).
The in vivo experiment showed that treating tumors
carrying the iCasp9 construct with dimerizer could effec-
tively reduce tumor size, but eventually tumors will grow
out again. To determine if in vivo resistance was the cause
for re-growth of the tumor, we injected CSCs-iCasp9-
IRES-GFP subcutaneously in mice and subsequently trea-
ted the mice for 5 consecutive days with dimerizer either
directly upon tumor injection or after the tumor reached
200 mm
3 (Fig. 3e). This extended treatment of the mice
after tumor formation induced a better and longer reduction
in tumor size and. Moreover, although the tumors eventu-
ally did grow out, this occurred with slower kinetics as
compared to the original line or the one-time treated mice.
In contrast, direct treatment with dimerizer after tumor
injection severely inhibited tumor growth. Only 1 in 4 mice
developed a tumor after 10 weeks, which displayed
remarkably slower growth rates than the untreated tumors.
In addition, this tumor did not show any GFP
? cells
(Fig. 3f), indicating that the iCasp9 construct was lost.
Discussion
We have shown that iCasp9, after chemical dimerization,
can induce apoptosis in cells that are resistant to conven-
tional therapy. First of all, cells that lack expression of Bax
and Bak show no apoptotic response to 5-FU treatment,
whereas, as expected, dimerization of iCasp9 induces rapid
induction of cell death independent of the presence of Bax
and Bak. Secondly, CSCs, known to be resistant for con-
ventional therapy [3, 5, 27], undergo rapid apoptosis when
exposed to dimerization of the iCasp9 construct, both in
vitro as well as in vivo.
Bax/Bak are not required for apoptosis induction by
dimerization of iCasp9 and this is not surprising as cas-
pase-9 acts downstream of the mitochondria. Although
several feed-forward ampliﬁcation loops have been
described between the intrinsic and extrinsic apoptosis
pathway [28–30], the induction by iCasp9 is not dependent
on this. So, loss of pro-apoptotic proteins can not block the
effect of dimerization of iCasp9, making a very efﬁcient
tool for inducing apoptosis in chemotherapy-resistant cells.
Also, the dimerization of iCasp9 in vivo is able to target
tumor cells and reduce tumor growth. The amount and
frequency of treatment with the dimerizer does inﬂuence
the effect, probably because the efﬁcacy of the delivery is
determined by this. A potential problem is that the con-
struct can be inactivated or lost by the cells when they are
pressure by treatment with the dimerizer. On the other
hand, multiple dimerizer treatments in mice having a
growing xenograft severely affected tumor growth at the
long term. Additionally, intervention treatment showed that
outgrowth of the tumor was almost completely abolished
by dimerizer treatment, indicating that CSCs can be efﬁ-
ciently targeted by this treatment in vivo.
As mentioned previously, CSCs are resistant to con-
ventional chemotherapy like 5-FU and oxaliplatin [3, 5]. In
agreement, recent ﬁndings conﬁrm the selective resistance
of CSC using the ABC transporter ABCB5 (Wilson). Here,
we use this knowledge and conﬁrm that that CSCs, marked
by high CD133 expression, are resistant to 5-FU, whereas
they are not to dimerization of iCasp9. This suggests that
CSCs are probably not completely resistant to all drugs and
this resistance can be overcome by efﬁcient induction of
cell death downstream in the apoptosis pathway. As the
dimerization of iCasp9 efﬁciently targets CSCs, their
resistance mechanism is probably more upstream in the
apoptosis pathway. Potentially, CSCs have blocked the
apoptosis induction at the level of the mitochondria.
Interestingly, in vitro treatment of breast CSCs with com-
pounds that target the mitochondria induces efﬁcient kill-
ing of these cells [31]. It would be interesting to determine
whether the resistance to upstream stimulation of the
apoptotic pathways and the here described sensitivity to
downstream pathway activation is also observed in primary
samples derived from patients with cancer. In the past we
have shown that also in freshly isolated tumor cells
selective resistance to chemotherapy is apparent. However,
whether these cells are sensitive to casp-9 dimerization
remains to be established. Alternatively, additional exper-
iments using drugs that activate downstream molecules in
the apoptosis pathway could therefore be very informative
for studying resistance in CSCs.
Because CSCs do not display any resistance to
dimerization of iCasp9, this construct is a potential
valuable tool for studying the role of CSCs in a growing
tumor. It has been suggested that CSCs drive tumor
growth and metastasis, but this has not been convincingly
proven in in vivo experiments. Current experiments show
that selection for expression of speciﬁc markers can
identify the human tumor fraction that is able to xenograft
in immunodeﬁcient mice. These experiments mainly show
that CSCs can initiate tumor growth upon transfer, which
could reﬂect enhanced adherence, survival or growth in a
foreign environment, but the necessity of CSCs to main-
tain tumor growth is unclear. Previously, circumstantial
evidence for the role of CSCs in a growing tumor has
been acquired by performing in vivo experiments to target
534 Apoptosis (2012) 17:528–537
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123CSCs in xenografts. For instance, when CRC xenografts
were treated with an antibody against delta-like 4 ligand
(DLL4), a ligand for the Notch signalling pathway, the
tumor growth slowed down. In addition, this antibody
treatment reduced stem cell frequencies, although only by
two-fold, indicating that not all CSCs were targeted [32].
A similar approach was used in a melanoma xenograft
model, in which CSCs can be identiﬁed by ABCB5
expression. Melanoma xenografts, treated with an anti-
body against ABCB5, which can induce antibody-depen-
dent cell-mediated toxicity, showed a clear reduction in
tumor growth [33]. Although this provides support for the
idea that CSC are required for tumor growth, it is not
clear whether the cytotoxic effect of the antibody treat-
ment is unique to the CSCs or results in bystander kill. In
the current in vivo experiments using dimerization of
iCasp9 we observe a highly effective induction of apop-
tosis. This is observed in all tumor cells, but not in the
stromal compartment. This therefore proves our hypoth-
esis that selective ablation is possible. Future experiments
will therefore have to be directed to CSC-speciﬁc
expression of the iCasp9 construct, which would allow a
timed and selective ablation of the CSC within a tumor
and would provide valuable information on the role of
these cells in growing tumors as compared to their role in
xenograft initiation.
In conclusion, dimerization of iCasp9 induces rapid and
efﬁcient cell death, even in cancer cells that are normally
resistant to conventional therapy due to overexpression of
anti-apoptotic molecules or loss of pro-apoptotic mole-
cules. Therefore, this construct is an interesting tool to
study the effect of apoptosis of CSCs in a tumor model.
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